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Abstract
Background
The regulation of microRNAs (miRNAs) at different stages of the progression of type 2 dia-
betes mellitus (T2DM) and their role in glucose homeostasis was investigated.
Methods
Microarrays were used to assess miRNA expression in skeletal muscle biopsies taken from
healthy individuals and patients with pre-diabetes or T2DM, and insulin resistant offspring
of rat dams fed a high fat diet during pregnancy.
Results
Twenty-three miRNAs were differentially expressed in patients with T2DM, and 7 in the
insulin resistant rat offspring compared to their controls. Among these, only one miRNA was
similarly regulated: miR-194 expression was significantly reduced by 25 to 50% in both the
rat model and in human with pre-diabetes and established diabetes. Knockdown of miR-
194 in L6 skeletal muscle cells induced an increase in basal and insulin-stimulated glucose
uptake and glycogen synthesis. This occurred in conjunction with an increased glycolysis,
indicated by elevated lactate production. Moreover, oxidative capacity was also increased
as we found an enhanced glucose oxidation in presence of the mitochondrial uncoupler
FCCP. When miR-194 was down-regulated in vitro, western blot analysis showed an
increased phosphorylation of AKT and GSK3β in response to insulin, and an increase in
expression of proteins controlling mitochondrial oxidative phosphorylation.
Conclusions
Type 2 diabetes mellitus is associated with regulation of several miRNAs in skeletal muscle.
Interestingly, miR-194 was a unique miRNA that appeared regulated across different stages
of the disease progression, from the early stages of insulin resistance to the development of
T2DM. We have shown miR-194 is involved in multiple aspects of skeletal muscle glucose
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metabolism from uptake, through to glycolysis, glycogenesis and glucose oxidation, poten-
tially via mechanisms involving AKT, GSK3 and oxidative phosphorylation. MiR-194 could
be down-regulated in patients with early features of diabetes as an adaptive response to
facilitate tissue glucose uptake and metabolism in the face of insulin resistance.
Introduction
MicroRNAs (miRNAs) are an abundant class of small, non-coding RNAs approximately 22
nucleotides long that have emerged as key regulators of gene expression through translational
inhibition and reduction in mRNA stability [1, 2]. They have been implicated in the regulation
of numerous biological processes in different tissues. Intensive research in recent years has
focused on the identification of miRNAs involved in pathophysiology [3, 4]. A growing num-
ber of miRNAs are now implicated in the development of type 2 diabetes mellitus (T2DM) [5]
and the regulation of glucose and lipid metabolism [6–8].
Type 2 diabetes constitutes one of the greatest pandemics of our time, with 387 million peo-
ple currently diagnosed, and 592 million people predicted to be affected by 2035 (IDF Diabetes
Atlas 2014). The rapid increase in T2DM over recent decades has been caused by the interac-
tion of genetic susceptibility and environmental factors, such as unhealthy diet and sedentary
lifestyle. Indeed, there is now strong evidence that altering the intrauterine environment can
result in changes in fetal development, thereby rendering an individual more likely to develop
T2DM even when adult risk factors are not present [9, 10]. Progressive impairment of glucose
homeostasis is also noted in many models of maternal diet-induced obesity, including in chow
fed offspring [11–13].
Skeletal muscle is the major site for postprandial, insulin-stimulated glucose uptake and
there is evidence that adult muscle structure and function are affected by an adverse intrauter-
ine environment. Muscle atrophy and intramuscular lipid accumulation and metabolic adapta-
tions normally associated with the onset of insulin resistance are observed in rat offspring
exposed to an obesogenic (cafeteria) diet in early life [14]. We previously showed that maternal
overnutrition, in the absence of obesity prior to conception, programs insulin resistance in the
adult rat offspring fed a normal chow diet from birth. This insulin resistance was associated
with alteration in skeletal muscle gene expression related to cytokine activation, inflammation
and mitochondrial dysfunction [15]. This occurred prior to any onset of obesity and without
consumption of a diet rich in fat or sugars.
The current study aimed to address the hypothesis that key miRNAs in skeletal muscle are
regulated early in the development of insulin resistance and involved in glucose homeostasis,
affecting long-term health. We thus examined miRNA signatures in skeletal muscle of pro-
grammed insulin resistant rats, before the onset of obesity and in the absence of traditional risk
factors, and unmedicated individuals who had been newly diagnosed with either pre-diabetes
or type 2 diabetes. We identified miR-194 as being commonly down-regulated in humans and
rats. Moreover, this miRNA was also decreased in a well established animal model of insulin
resistance (high fat diet). The consistency of our findings across models and species at different
stages of metabolic disease provided a strong rationale to examine the function of this unique
microRNA. We thus investigated the effects of this down-regulation on glucose homeostasis
and signaling pathways in vitro.
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Materials and Methods
Human samples
Males with pre-diabetes (PD, n = 5) or type 2 diabetes mellitus (T2DM, n = 6) participated in
the study along with age and sex-matched healthy volunteers (H, n = 5). The study was
approved by the Alfred Hospital Ethics Committee and performed in accordance with the Dec-
laration of Helsinki. All participants provided written, informed consent. Pre-diabetic and dia-
betic status were confirmed with the use of standard criteria (PD: fasting plasma glucose
between 6.1 and 6.9 mmol/L or a 2-hour blood glucose level between 7.8 and 11 mmol/L,
T2DM: fasting plasma glucose>7.1 mmol/L or a 2-hour blood glucose level of>11.1 mmol/L,
after a 75-g oral glucose load [oral glucose tolerance test]). All the patients were unmedicated.
Diet and physical activity were not controlled nor recorded during the study. However, partici-
pants were advised to abstain from alcohol, caffeine and moderate-vigorous exercise for the 24
hours prior to biopsy which was performed after an overnight fast.
Skeletal muscle biopsies were obtained from the vastus lateralis of fasted participants using
standard aseptic technique and local anesthesia. In brief, a ~7 mm skin incision was made, and
the fascia opened. A side cutting muscle biopsy needle was passed through the incision to
obtain ~100mg of muscle tissue under suction. All biopsies were cleaned then snap frozen in
liquid nitrogen and subsequently stored at -80°C until further analysis.
Animals
Animals were provided humane care in line with the “Guide for the Care and Use of Labora-
tory Animals” (NIH publication 86–23, 1985). Animal experiments were approved by the
Alfred Medical Research and Education Precinct Animal Ethics Committee and conducted in
strict accordance with the National Health and Medical Research Council (NHMRC) of Aus-
tralia Guidelines for Animal Experimentation.
Rat offspring of chow or high fat-fed dams. Animal husbandry and experimental diet
details have been previously published [15]. Briefly, female Sprague-Dawley breeder rats were
fed either a standard chow diet (C, 7% total fat– 0.5% saturated fat, 10% sucrose wt/wt, 16.1
MJ/Kg; AIN93G, Specialty Feeds, Glen Forest, WA, Australia) or a diet rich in saturated fat
(sourced mainly from animal lard) and sucrose (HF, 23.5% total fat– 9.83% saturated fat, 20%
sucrose wt/wt, 19.6MJ/Kg; SF08-023, Specialty Feeds) for the 3 weeks prior to mating and
throughout pregnancy and lactation. Male offspring of control (n = 6) and HF (n = 5) dams
were weaned at postnatal day 21 and maintained on a standard chow diet (ad libitum) until
they reached 12 months. Blood was collected via cardiac puncture and glucose determined by
handheld glucometer (Accu-Chek Roche, Castle Hill, NSW, Australia), plasma assayed for
insulin by ELISA (Kit 90010, Crystal Chem, Downers Grove, IL, USA).
High fat-fed mice. A high fat diet (HFD) was chosen as a model to induce skeletal muscle
insulin resistance, as it has been well-characterized in C57BL/6 mice [16–18]. Male C57BL/6
mice aged 8 weeks were fed either a standard chow diet (8% total fat, 14 MJ/kg; Specialty
Feeds) or a high fat diet (HFD, 43% total fat (lard), 19 MJ/kg; SF04-001, Specialty Feeds) for a
subsequent 8 weeks (n = 9–10 per group) as this duration of diet robustly induces skeletal mus-
cle insulin resistance [18]
For tissue collection, all animals (i.e. rat offspring of chow or high fat-fed dams, and high
fat-fed mice) were anaesthetized using inhaled isofluorane. Skeletal muscle (soleus) was col-
lected from the hind limb and immediately snap frozen in liquid nitrogen and stored at -80˚C
for further analysis.
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RNA extraction and miRNAmicroarray
Total RNA (including miRNAs) was extracted from frozen tissues using the TRIZOL reagent
(Invitrogen, Mount Waverley VIC, Australia) following the manufacturer’s recommended pro-
tocol. Concentration and purity of the total RNAs were assessed by spectrophotometer (Nano-
drop 1000, Nanodrop Technologies, Wilmington, DE, USA) and RNA integrity was verified
using an Agilent 2100 bioanalyzer (Agilent Technologies, Mulgrave, VIC, Australia).
MiRNAmicroarrays were performed at the Ramaciotti Centre for Genomics (University of
New South Wales, NSW, Australia) using Agilent arrays and following manufacturer’s instruc-
tions. Briefly, Cy3-labeled RNA was generated using the Agilent’s miRNA Complete Labeling
and Hyb Kit with a sample input of 100 ng of total RNA. Hybridization of labeled miRNA to
either 8x60K Human or 8x15K Rat miRNA microarray slides (based on miRBase release 16.0)
was for 20 hours at 55°C on a rotator at 20 rpm. The slides were then washed and scanned with
an Agilent microarray scanner. Extracted data were analyzed with GeneSpring GX7.3 expres-
sion analysis software (Agilent Technologies). In this study, Human miRNA microarray slides
contained 1205 human miRNAs, and rat miRNA microarray slides contained 679 mature rat
miRNAs. The data discussed in this publication have been deposited in the National Center for
Biotechnology Information (NCBI)'s Gene Expression Omnibus (GEO) and are accessible
through GEO Series accession number GSE68226 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE68226). Analysis of the miR microarray data was performed in GeneSpring
GX7.3 expression analysis software. Differentially expressed miRs were identified following a
one way-ANOVA with Student-Newman-Keuls post hoc tests in human samples, and unpaired
Student t-tests in rat samples. We then aligned data from both species in order to identify miR-
NAs that were commonly deregulated.
Cell culture
L6 rat myoblast cells were maintained in Dulbecco's modified Eagle's medium (DMEM) con-
taining 5mM glucose and supplemented with 10% fetal bovine serum and 1% penicillin/strep-
tomycin. Once cells reached confluence, the medium was replaced with DMEM supplemented
with 2% horse serum and 1% penicillin/streptomycin to promote myoblast differentiation into
myotubes.
Transfection of miR-194 inhibitor
The amount of miRNA inhibitor needed to efficiently down regulate a target gene or inhibit
miRNA function can vary greatly, depending on the miRNA, the cell line, and the chosen anal-
ysis method. To determine the optimal concentration, experiments using varying miR-194
inhibitor concentrations (5–100 nM) were performed. A concentration of 100 nM proved opti-
mal, giving robust and consistent efficacy inducing a 35 fold decrease in miR-194 expression in
the cells (qPCR, data not shown).
Fully differentiated L6 cells were transfected with either a miR-194 inhibitor or a negative
control (Applied Biosystems, #MH10004 and #4464076) using Lipofectamine RNAiMAX
(Invitrogen) following the manufacturers’ recommended protocol. Briefly, L6 cells, seeded on
12-well plates, were incubated with 200μl of opti-MEM supplemented with 2% horse serum,
100 nM of miR inhibitor or control (1μl of a 20 μM stock) and 1% of the transfection agent.
After 6 h, the supernatant was replaced with fresh medium and cultured for another 42 h. Cells
were then either harvested and subjected to RT-qPCR andWestern blot analyses or used for
the functional assays described below.
Cell viability and integrity was monitored during the transfection period. Of note, all the
functional assays were also performed in untransfected cells and in presence of the transfection
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agent (i.e. lipofectamine) only. No differences were observed between untransfected cells, lipo-
fectamine only and miR negative control.
miR quantitative real-time PCR
MiR-194 levels were assessed in human and rodent tissues, and in transfected L6 cells using
Taqman microRNA assays (Applied Biosystems, Carlsbad, CA, USA). RNA (2 μg) from the
skeletal tissues was reverse transcribed using the specific miR-194 stem-loop RT primers
(Applied Biosystems, #000493) and then subjected to quantitative PCR on the Applied Biosys-
tems 7500 Real-Time PCR System. Data were normalized to RNU44 (for human tissues,
Applied Biosystems, #001094) or U6 snRNA (for rodent tissues and cells, Applied Biosystems,
#001973) and analyzed using the ΔΔCt method [19].
Basal and insulin-stimulated glucose uptake
Glucose uptake was determined by the 2-deoxy-glucose method. Following overnight serum
depletion, cells were pre-treated with or without 100nM insulin for 30 min in DMEM contain-
ing 5 mM glucose, before a 20 min-treatment with or without insulin in glucose-free media.
Following treatment, glucose uptake was assayed by incubating cells with 2-deoxy-[3H]-d-glu-
cose (1 μCi/ml, 26.2 Ci/mmol) for 10 min. Cell-associated radioactivity was determined by lys-
ing the cells with 0.3M NaOH, followed by liquid scintillation counting and protein
determined with the Pierce BCA Protein Assay (ThermoScientific, Rockford, IL, USA). Non-
specific uptake was assessed with the use of cytochalasin-B (10 μmol/L), a vesicle transport
inhibitor, and was subtracted from total uptake.
Basal and insulin-stimulated glycogen synthesis
In vitro rates of basal and insulin-stimulated glucose utilization via incorporation into glycogen
were determined in L6 cells after miR transfection. L6 myotubes were serum deprived over-
night in DMEM (5mM glucose, 1% penicillin/streptomycin) and washed twice with warm PBS
prior to incubation at 37 °C with or without 100 nm insulin, and 0.8μCi/ml [U14C]-d-glucose
for 1 hour. The incubation was terminated by three washes with ice-cold PBS prior to lysis in
1M KOH. Cellular glycogen was precipitated from lysates using glycogen (25mg/ml), saturated
Na2SO4, and ice-cold absolute EtOH, and incubated overnight at -80 °C. The following day,
samples were homogenized by sonication in ice water and associated radioactivity was deter-
mined by liquid scintillation counting. Protein concentration was determined with the Pierce
BCA Protein Assay (ThermoScientific).
Basal and insulin-stimulated lactate production
In vitro rates of basal and insulin-stimulated glycolysis were determined in L6 cells after miR
transfection via measure of lactate production. L6 myotubes were serum deprived for 4 hours
in DMEM (5mM glucose, 1% penicillin/streptomycin) and washed twice with warm PBS prior
to a 2 hour-incubation at 37 °C with or without 100 nm insulin [20]. Media was then removed
and an acid extraction was carried out. Lactate production was determined enzymatically using
L-Lactate (Sigma) to generate standard curve.
Glucose oxidation
L6 cells were plated in 12-well plates and serum starved overnight prior to 1 hour pre-incuba-
tion with 1mM glucose-Krebs buffer. Krebs was removed and L6 were treated with saline or
FCCP in Krebs buffer containing 1μCi/mL [14C]-glucose for 2 hours. [14CO2] produced during
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glucose oxidation was collected using a CO2 trapping method. 250μL of buffer was removed
and carefully added to a 20mL scintillation vial containing a 1.7mL tube with a 500μL tube
inside. 300μL of 1M NaOH was added into the 500μL tube and an equal volume of 1M acetic
acid was added to the scintillation vial prior to incubation in a shaking incubator for 2 hours at
37°C. Shaking allows the [14CO2] to be released and captured in the NaOH. Following incuba-
tion, the NaOH containing 500μL tube was removed and placed into a separate 5mL scintilla-
tion vial and associated radioactivity was determined by liquid scintillation counting. Protein
concentration was determined with the Pierce BCA Protein Assay (ThermoScientific).
Western blots
Muscle samples were homogenized in lysing buffer (20mMHEPES, 2M EDTA, 50mMNaF,
5mMNa4P2O7, 1% NP40, 1mMNa3VO4, 1mMDTT, 0.05% SDS) containing a protease
inhibitor cocktail (Roche Diagnostics, Meylan, France). The homogenates were centrifuged at
12,000 g for 10 min and the supernatant recovered. Protein content was then determined with
the Pierce BCA Protein Assay (ThermoScientific). Proteins were reduced and denatured by
boiling lysates in Laemmli buffer at 95°C for 5 min. Lysates were then separated by gradient
(4–20%) SDS-polyacrylamide gel electrophoresis (Novex, Carlsbad, CA, USA) and transferred
to PVDF membranes (GE Healthcare, Rydalmere, NSW, Australia). Blots were blocked 1 h at
room temperature with 5% non-fat dry milk in TBST (20mM Tris-HCl pH 8.0, 135mM NaCl,
0.1% Tween-20). Membranes were then incubated with anti-phosphoAkt(Ser473) (1/2000,
#4058, Cell Signaling Technology, Danvers, MA, USA), anti-total Akt (1/2000, #9272, Cell Sig-
naling Technology), anti-phosphoGSK3α/β(Ser21/9) (1/1000, #9331, Cell Signaling Technol-
ogy, the lower band representing phosphoGSK3β was quantified), and anti-total GSK3β (1/
2000, #9315, Cell Signaling Technology)antibodies overnight. After several washes with TBST,
membranes were exposed to anti-rabbit horseradish peroxidase-conjugated secondary anti-
body for 1 hr. Antibody binding was then detected using the ECL Plus reagents (GE Health-
care) and signals were quantified using the Molecular Imager ChemiDoc and Quantity One
1-D analysis software (Bio-Rad Laboratories, Hercules, CA, USA). Beta-actin (#4967, Cell Sig-
naling Technology) was used as an internal protein loading control for the AKT and GSK3β
blots. The same membranes were used to detect both the phosphorylated and the total forms of
each protein of interest (i.e. AKT and GSK3β) and β-actin. The ratio between the phosphory-
lated and the total forms of both AKT and GSK3β was then calculated.
The Abcam anti-oxidative phosphorylation complexes (OXPHOS) kit was used to deter-
mine the relative levels of the 5 OXPHOS complexes (1/250, #ab110413, Abcam, Waterloo,
NSW, Australia). This kit contained a cocktail of 5 antibodies, one each against complex sub-
unit. The samples were heated at 50°C for 5 min then resolved using SDS-PAGE. Membranes
were exposed to anti-mouse horseradish peroxidase-conjugated secondary antibody, and sig-
nals revealed with different durations of exposure. Due to denaturation conditions that differed
from prior analyses, α-tubulin (#2144, Cell Signaling Technology) was measured on different
membranes.
Sample size and statistical analysis
Statistical analyses were performed with SigmaStat software (Systat Software Inc., San Jose,
CA, USA) and SPSS software (IBM, Armonk, NY, USA).
Although the number of patients and animals was small, a 25% or greater change in gene
expression at p<0.05 was identified with power between 87% (human) and 99% (mice).
For qPCR and western blots, normally distributed data were compared by unpaired t-tests
or one way-ANOVA with Student-Newman-Keuls post-hoc tests as appropriate. Non-normally
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distributed data were compared by Mann-Whitney rank sum tests or Kruskal-Wallis 1-way
ANOVA on ranks with Student-Newman-Keuls post-hoc tests as appropriate. Relationships
between miR expression assessed by qRT-PCR and the insulin resistance index (HOMA-IR)
were assessed using the Pearson or the Spearman correlation coefficient as appropriate. Func-
tional data (glucose uptake, glycogen synthesis, glucose oxidation and lactate production) were
analyzed by 2-way ANOVA with Student-Newman-Keuls post-hoc tests or Kruskal-Wallis
1-way ANOVA on ranks with Student-Newman-Keuls post-hoc tests as appropriate. Results
are expressed as mean±SEM unless otherwise indicated. Cell culture data represent a minimum
of 4 individual experiments, with 4 technical replicates. A P value of<0.05 was considered
significant.
Results
Phenotypic characteristics (humans and rats)
In this study, we used skeletal muscle biopsies taken from unmedicated, newly diagnosed
patients with pre-diabetes or type 2 diabetes and healthy volunteers, and soleus muscle from
adult rat offspring from dams fed a high fat diet or chow diet during pregnancy and lactation.
Patients with pre-diabetes and type 2 diabetes were obese, hyperglycemic and/or glucose
intolerant and hyperinsulinemic compared to age-matched healthy participants (Table 1).
Adult rat offspring from dams fed a HF diet were not overweight though they presented
with higher adiposity, and were hyperinsulinemic (Table 1). More detailed characteristics on
these programmed insulin resistant rats are published elsewhere [15].
We utilised the exact experimental approach as reported in the study by Turner et al., (i.e
same mice age and background, same diet, same diet duration) which robustly found 8 weeks
of HFD induced skeletal muscle insulin resistance [18]. We confirmed the HFD increased body
weight gain, fat mass, glucose intolerance and hyperinsulinaemia using body composition anal-
ysis and an oral glucose tolerance test at 6 weeks of diet intervention (unpublished data). These
data replicate the same effects of the HFD reported by Turner et al., and provide evidence skel-
etal muscle insulin resistance is likely induced in our cohort of mice.
Table 1. Phenotypic characteristics.
HUMAN Healthy Pre-diabetes Type 2 diabetes
Age (yrs) 48±3 52±2 53±2
BMI (kg/m2) 25±1 34±1* 33±2*
Fasting glucose (mM) 5.2±0.2 6.1±0.2 11.2±1.6*
OGTT 2hrs (mM) 4.9±0.5 8.2±0.4 20.4±1.4*
Fasting insulin (mU/L) 4.0±0.5 11.2±2.0** 12.8±1.8**
HOMA-IR 1.0±0.1 3.4±0.7* 6.2±1.3**
RAT Control High fat p-value
Body weight (g) 773±38 782±69 0.91
Glucose (mM) 6.35±0.38 7.35±1.24 0.38
Insulin (mU/L) 40.0±2.5 56.2±6.1 0.02
HOMA-IR 11.4±0.9 18.9±4.68 0.09
Data were obtained from healthy volunteers (n = 5), or patients with pre-diabetes (n = 5) or type 2 diabetes
mellitus (n = 6) and from rat offspring of control (n = 4) or high fat (n = 6) dams at 1 year of age. Values are
expressed as mean ± SEM. P-values were determined using 1-way ANOVA followed by Student-Newman-
Keuls post-hoc tests for human data (*p<0.05 and **p<0.01 vs healthy), or Student’s t-test or Mann-
Whitney U test as appropriate for rat data. BMI: body mass index, OGTT: oral glucose tolerance test.
doi:10.1371/journal.pone.0155108.t001
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Differential expression of microRNAs in insulin resistant skeletal muscle
from rodents and humans
To identify microRNAs that are regulated early in insulin resistance and in the progression to
T2DM, we performed miRNA microarray analysis on the muscle samples. We identified 13
Table 2. Differentially expressedmicroRNAs identified by microarray.
Differentially expressed microRNAs in human skeletal muscle
Systematic name FC PD vs H FC T2DM vs H p-value
Upregulated microRNAs
hsa-miR-542-5p 22.64 12.58 0.042
hsa-miR-944 2.19 3.48 0.049
hsa-miR-214 1.85 2.65 0.049
hsa-miR-382 2.88 1.98 0.049
hsa-miR-206 1.25 1.73 0.012
hsa-miR-29b-1 1.31 1.53 0.0001
hsa-miR-489 1.36 1.43 0.004
hsa-miR-3907 1.23 1.31 0.015
hsa-miR-139-5p 1.07 1.28 0.030
hsa-miR-29b 1.05 1.24 0.001
hsa-miR-628-5p 1.19 1.22 0.019
hsa-miR-128 1.35 1.20 0.023
hsa-miR-125b 1.19 1.11 0.009
Downregulated microRNAs
hsa-miR-30d -1.16 -1.10 0.035
hsa-miR-106b -1.29 -1.25 0.048
hsa-miR-185 -1.47 -1.41 0.029
hsa-miR-194 -1.60 -1.41 0.018
hsa-miR-4271 -1.20 -1.49 0.042
hsa-miR-3141 -1.45 -1.59 0.006
hsa-miR-4306 -1.59 -1.61 0.037
hsa-miR-363 -1.33 -1.68 0.045
hsa-miR-142-3p -1.86 -1.86 0.047
hsa-miR-515-5p -4.45 -8.59 0.003
Differentially expressed microRNAs in rat skeletal muscle
Systematic name FC HF vs C p-value
Upregulated microRNAs
rno-miR-582 18.12 0.009
rno-miR-181d 7.70 0.014
Downregulated microRNAs
rno-miR-511 -1.20 0.027
rno-miR-322 -1.22 0.008
rno-miR-425 -1.41 0.044
rno-miR-499 -1.98 0.045
rno-miR-194 -2.88 0.019
Fold-change (FC) in microRNA expression is shown in pre-diabetics (PD) or type 2 diabetics (T2DM) vs
healthy participants (H) for human data, and in offspring from high fat-fed dams (HF) vs offspring from chow
fed dams (C). P-values were determined using 1-way ANOVA followed by Student-Newman-Keuls post-
hoc tests for human data, or Student’s t-test for rat data.
doi:10.1371/journal.pone.0155108.t002
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up-regulated and 10 down-regulated miRs in the skeletal muscle of patients with T2DM, along
with 2 up-regulated and 5 down-regulated miRs in the insulin resistant offspring of fat-fed rats
compared to their controls (Table 2). Among these, one miR was similarly regulated; indeed,
miR-194 expression was significantly reduced in both models.
The expression levels of miR-194 were validated by qPCR, demonstrating a 50% reduction
in expression in the skeletal muscle of individuals with pre-diabetes and diabetes (Fig 1A) and
a 25% decrease in the skeletal muscle of insulin resistant rats (Fig 1B). Moreover, we identified
a negative correlation between homeostatic model assessment index of insulin resistance
(HOMA-IR, reported in Table 1) and miR-194 expression levels (r = -0.69, p = 0.01 in humans,
r = -0.65, p = 0.04 in rats, Fig 1C and 1D), indicating an association of miR-194 with insulin
resistance.
To further confirm down-regulation of miR-194 in the insulin resistant state, we measured
its expression in skeletal muscle from mice fed a HFD for 8 weeks, a well characterized mouse
model of insulin resistance [18]. Indeed, we found a 37% decrease in the skeletal muscle of
these animals (Fig 2).
Down-regulation of miR-194 in vitro promotes glucose metabolism
To investigate the functional effect of down-regulation of miR-194 expression in the develop-
ment of T2DM, we performed in vitro functional assays.
We firstly assessed basal and insulin-stimulated glucose uptake in the L6 muscle cell line
after inhibiting miR-194 expression. Differentiated L6 cells were transfected with either a miR
negative control or miR-194 inhibitor. After 48 hours, we measured uptake of the glucose ana-
logue, 2-deoxy-D-glucose. Inhibition of miR-194 induced a 53±8% increase in basal glucose
uptake and a 40±20% increase in insulin-stimulated glucose uptake into the muscle cells com-
pared to the transfection control (p<0.05 for both, Fig 3A).
To determine if the differences in glucose uptake contributed to glycogen storage, we then
measured glycogen synthesis. Compared to control, miR-194 inhibition increased glycogen
synthesis by 34±3% under basal conditions and 23±13% with insulin stimulation (p<0.05 for
both, Fig 3B). Additionally we measured lactate production to assess glycolysis. Under basal
conditions, we found lactate production was significantly increased following miR-194 inhibi-
tion compared to control (9±4%, p<0.05, Fig 3C). When stimulated with insulin, lactate pro-
duction increased by 18±7% in control cells while there was no further increase in cells
transfected with the miR-194 inhibitor (p<0.05, Fig 3C).
To further investigate the fate of this increased glucose uptake in the miR-194 inhibited
cells, we measured glucose oxidation. Although there was no effect of miR-194 inhibition on
the basal glucose oxidation rate, we found an increased glucose oxidation when the cells were
treated with the mitochondrial uncoupler FCCP (Fig 3D).
Down-regulation of miR-194 in vitro activates the insulin signaling
pathway and oxidative phosphorylation
To address the possible mechanisms by which miR-194 regulates glucose metabolism, we
examined components of signaling pathways contributing to glucose metabolism. Phosphory-
lation of AKT (Ser473) and GSK3β (Ser9), relative to total expression, in response to insulin
were increased by 43±9% and 71±4% respectively (p<0.05) in L6 cells transfected with the
miR-194 inhibitor (Fig 4). There was no effect on phosphorylation of these proteins by miR-
194 inhibition under basal conditions.
We also examined protein expression of mitochondrial oxidative phosphorylation
(OXPHOS) complexes (Fig 5). Complexes I (NADH dehydrogenase, NDUFB8), II (succinate
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dehydrogenase, SDHB), IV (cytochrome c oxidase, MTCO1), and V (ATP synthase, ATP5A)
were increased by between 30 to 85% (p<0.05) when miR-194 was inhibited compared to con-
trol (Fig 5). Complex III (Q-cytochrome c oxidoreductase, QCRC2) was not different.
Discussion
Growing evidence indicates an important role of miRNAs in metabolism and glucose homeo-
stasis; thus miRNAs could be involved in the pathogenesis of type 2 diabetes. This study exam-
ined the role of microRNAs at different stages in the programming and progression of T2DM.
The focus was on skeletal muscle which accounts for over 80% of glucose disposal in the body.
Fig 1. miR-194 expression in the skeletal muscle of human participants and rat offspring and correlations with HOMA-IR.miR-194
expression was validated by qPCR in human (A) and rat samples (B) (n = 4–6 per group). Values are expressed as mean ± SEM. P-values
were determined using 1-way ANOVA followed by Student-Newman-Keuls post-hoc test for human data (*p<0.05 vs healthy), or Student’s
t-test for rat data (*p<0.05 vs control). Correlation between miR-194 expression and HOMA-IR in human (C) and rat (D) was assessed
using Pearson’s or Spearman’s correlation test as appropriate. R and p-values are indicated on the graphs.
doi:10.1371/journal.pone.0155108.g001
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The results of this study reveal an important role of miR-194 in influencing glucose metabolism
in association with the progression from insulin resistance to type 2 diabetes. Indeed, we identi-
fied miR-194 as being down-regulated in skeletal muscle of insulin resistant rats from HF fed
dams, high fat fed mice, and humans with pre-diabetes and T2DM. We investigated the func-
tional role of miR-194 in skeletal muscle cells and showed that miR-194 down-regulation is
associated with: 1) increased basal and insulin-stimulated glucose uptake, 2) increased glycoly-
sis and incorporation into glycogen, 3) increased AKT and GSK3β phosphorylation in response
to insulin stimulation, 4) increased glucose oxidation capacity, and 5) increased basal protein
expression of mitochondrial oxidative phosphorylation complexes in skeletal muscle. Thus,
miR-194 could be down-regulated in patients with early features of diabetes as an adaptive
response to facilitate glucose metabolism in the face of insulin resistance. These findings pro-
vide mechanistic insight into the role of microRNA regulation of skeletal muscle glucose
homeostasis.
Insulin resistance alters the microRNA signature in skeletal muscle
The rapid increase in T2DM over the past decades has been caused by interactions between
genetic susceptibility and environmental factors, such as unhealthy diet and sedentary lifestyle
[21]. Epigenetics is now understood to be an important regulator during critical periods of
development which can permanently alter phenotype. In particular, miRNAs have emerged as
key regulators of gene expression [2]. They have also been implicated in the regulation of glu-
cose and lipid metabolism and in diabetes [7, 8, 22–25]. To identify miRs involved in the sus-
ceptibility and progression to T2DM, we performed microRNA microarrays using a combined
experimental and clinical approach involving: 1) a rat model of maternal high fat feeding dur-
ing gestation and lactation that induces the development of insulin resistance in chow fed off-
spring in the absence of obesity, and 2) human skeletal muscle biopsies from patients across
the spectrum from healthy to pre-diabetes and established type 2 diabetes.
Fig 2. MiR-194 expression in the skeletal muscle of mice fed a high fat diet.MiR-194 expression was
measured by qPCR in the skeletal muscle frommice fed a chow or a high fat diet for 8 weeks (n = 9–10 per
group). Values are expressed as mean ± SEM. P-values were determined using Student’s t-test (*p<0.05 vs
chow fed mice).
doi:10.1371/journal.pone.0155108.g002
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Male offspring of HF dams demonstrated higher circulating insulin levels and, although
their body weight was not different from controls, there was increased regional adiposity [15].
The development of insulin resistance is commonly seen prior to the development of T2DM
[26], and has also been described in several models of maternal overnutrition [9]. The detri-
mental effects of overnutrition during fetal and early postnatal life (i.e. increased adiposity,
Fig 3. Effect of miR-194 inhibition on glucose homeostasis in L6 cells. Basal or insulin-stimulated glucose uptake (A), glycogen
synthesis (B) and lactate production (C) were assayed in L6 cells 48 hours after transfection with a miR-194 inhibitor. Glucose oxidation
(D) was also measured in these transfected cells under basal conditions or after treatment with the mitochondrial uncoupler FCCP.
Values are expressed as mean ± SEM of 4–6 individual experiments, with 4 technical replicates. P-values were determined using 2-way
ANOVA (normally distributed data) or Kruskal-Wallis 1-way ANOVA on ranks (non-normally distributed data) followed by Student-
Newman-Keuls post-hoc tests (* p<0.05 vs. control, # p<0.05 vs. basal).
doi:10.1371/journal.pone.0155108.g003
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hypertension, insulin resistance, and obesity have been supported by numerous studies in ani-
mal models [11, 12]. Patients with pre-diabetes or T2DM presented with abnormal fasting
plasma glucose levels and/or abnormal glucose levels 2 hours after an oral glucose tolerance
test (OGTT). Interestingly, in our human cohort, 4 out of 5 volunteers with pre-diabetes and 3
out of 6 volunteers with type 2 diabetes had a family history of T2DM.
Microarrays revealed an altered miR signature in the skeletal muscle of insulin resistant
rats, patients with pre-diabetes and patients with T2DM. Among the miRs that were differen-
tially expressed in the skeletal muscle of patients with PD/T2DM, and in the insulin resistant
rat offspring compared to their controls, some have been previously described in the literature
as linked to T2DM. For example, miR-206 and miR-29b are known to be significantly upregu-
lated in the context of diabetes [27, 28] and such increase was confirmed in our human cohort.
Interestingly, a unique microRNA was regulated across both species: indeed, miR-194
expression was significantly reduced by 25 to 50% in both models. A negative correlation
between miR-194 expression and the HOMA-IR also indicated an inverse association of this
miR with insulin resistance. Moreover, we measured miR-194 expression in the skeletal muscle
of high fat fed mice with established insulin resistance [18] and also showed a 37% decrease in
the skeletal muscle of these animals. This experimental model has been found to induce whole-
body insulin resistance which is initiated by impaired hepatic insulin action (after 1 week) and
Fig 4. Effect of miR-194 inhibition on AKT and GSK3β expression in L6 cells. Expression of the phosphorylated and total forms
of AKT (A) and GSK3β (B) were measured byWestern blot in L6 cells 48 hours after transfection with a miR-194 inhibitor. Ratios
phosphorylated:total are expressed as mean ± SEM (n = 3 per group). Representative blots are shown below the graphs. P-values
were determined using 2-way ANOVA (normally distributed data) or Kruskal-Wallis 1-way ANOVA on ranks (non-normally
distributed data) followed by Student-Newman-Keuls post-hoc tests (* p<0.05 vs. control, # p<0.05 vs. basal).
doi:10.1371/journal.pone.0155108.g004
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exacerbated by skeletal muscle insulin resistance (observed after 3 weeks) and is associated
with the accumulation of specific bioactive lipid species [18]. A role for miR-194 in type 2 dia-
betes has not yet been described in the literature; however, Zhang J. et al. showed a decreased
hepatic expression of miR-194 in the adult offspring of high fat fed dams [29]. Of note, we also
found a decreased miR-194 expression in the adipose tissue from our human cohort (-21% in
patients with pre-diabetes, -38% in patients with T2DM, data not shown).
In silico prediction of miRNA target genes is an important tool to determine the biological
pathways regulated by miRNAs [30–32]. A computational prediction of miR-194 target genes
has suggested several targets linked to T2DM signaling pathways (ATM, AKT2, KCNJ11,
MAPK1, SOCS2), insulin signaling (AKT2, ATM, CRK, FOXO1, GRB10, INPP5K, MAPK1,
PRKAR1A) and AMPK signaling (ADRAP1A, AKT2, ATM, CHRNAS, MAPK1, PPAT,
PPP2R2C, PRKAR1A).
miR-194 down-regulation promotes multiple aspects of glucose
metabolism in skeletal muscle
When studying the effects of miR-194 inhibition in L6 myocytes, we found that down-regula-
tion of miR-194 resulted in an increased glucose uptake into the muscle cells and incorporation
into glycogen both basally and in response to insulin. The potentiation of glucose metabolism
in response to insulin can be explained by upregulation of the insulin signaling pathway.
Indeed, our study revealed augmented levels of insulin-stimulated phosphorylation of AKT
and GSK3β by miR-194 inhibition. AKT is normally activated by insulin through phosphoryla-
tion of the Thr 308 and Ser 473 sites respectively [33]; then AS160 (AKT substrate of 160 kDa)
is phosphorylated and inhibited. This induces the redistribution of GLUT-4 from intracellular
vesicles to the plasma membrane, thus regulating glucose uptake [34]. AKT is also involved in
the regulation of glycogen synthesis through the serine/threonine kinase glycogen synthase
Fig 5. Effect of miR-194 inhibition on protein expression of the oxidative phosphorylation complexes expression in
L6 cells. Expression of the oxidative phosphorylation (OXPHOS) complexes I to V of the electron transport chain was
measured by western blot in L6 cells 48 hours after transfection with a miR-194 inhibitor. Data are expressed as
mean ± SEM (n = 3 per group). Representative blots are shown. P-values were determined using t- tests (*p<0.05 and
**p<0.01 vs control).
doi:10.1371/journal.pone.0155108.g005
miR-194 and Muscle Glucose Metabolism
PLOSONE | DOI:10.1371/journal.pone.0155108 May 10, 2016 14 / 20
kinase 3 (GSK3). This enzyme consists of two isoforms, GSK3α and GSK3β, is inactivated
through phosphorylation on stimulation and inactivates glycogen synthase (GS) by phosphor-
ylation [35]. It has been shown that GSK3 is overexpressed and overactive in skeletal muscle in
obesity and T2DM [36, 37] [38]. Moreover, exposure to maternal obesity during the pericon-
ceptional period results in the programming of changes to molecules downstream of AKT,
GLUT-4 and GSK3 [39]. Thus, reduced miR-194 may elevate glucose uptake and its incorpo-
ration into glycogen by activating AKT and inactivating GSK3 through phosphorylation.
We have also shown an increased glycolysis in response to the down-regulation of miR-194,
as indicated by an elevated lactate production in transfected cells. Interestingly, the absence of
further increase of lactate production when transfected cells are treated with insulin may indi-
cate that the glycolytic rate within miR-194 inhibited cells is already operating at maximal
capacity.
Glucose oxidation rates were unaffected by miR-194 inhibition under basal conditions, but
in the presence of the mitochondrial uncoupler FCCP, cells had an increased oxidative capac-
ity. These data suggest a reduction in miR-194 may allow greater oxidation of substrate, specifi-
cally glucose, under periods of increased substrate supply or under metabolic stress where
greater ATP turnover is required. Considering glucose oxidation was assayed under basal con-
ditions, it might be interesting to determine whether miR-194 inhibition can increase glucose
oxidation under simulated nutrient excess.
In line with our oxidative phenotype, L6 muscle cells transfected with a miR-194 inhibitor
had higher protein expression of several complexes of the mitochondrial oxidative phosphory-
lation (OXPHOS) chain, a proxy measure for mitochondrial volume. A greater mitochondrial
volume provides a likely explanation for the increase in oxidative capacity we observed in miR-
194 silenced cells.
The tightly controlled process of mitochondrial OXPHOS, which involves 5 different pro-
tein complexes (Complex I-V), is responsible for the production of ATP. Deterioration of
mitochondrial function is often present in metabolic diseases [40]; altered oxidative metabo-
lism and mitochondrial structure, and impaired biogenesis have indeed been described in mod-
els of insulin resistance or T2DM [41, 42]. MiRs also play a role in the regulation of
mitochondrial function, either under physiological or pathological conditions [43]. We have
also shown that offspring of dams fed a high fat diet during pregnancy and lactation suffered
from a decline in mitochondrial OXPHOS activity in adulthood [15]. Conversely, we observed
that decreased expression of miR-194 for a short term (48 hours in vitro) is able to increase
muscle mitochondrial oxidative capacity potential through increased mitochondrial OXPHOS.
This may be an early compensatory mechanism to adjust to excess substrate supply and glyce-
mia observed in metabolic disorders such as T2DM.
Limitations
There is no gold standard for measuring miR expression; however, microarray and q PCR are
the most recognized methods for evaluating miRs [44, 45]. Down-regulation of miR-194 iden-
tified by microarray was indeed validated by qPCR, showing good correlation between micro-
array and qPCR, and discarding the possibility of a false positive which can be high with
microarray studies.
The microarray data from humans and rats provided a basis for the a priori hypothesis that
miR-194 would be differentially expressed between the various models when assessed by
qPCR.Though relatively small, the number of participants was nevertheless sufficient to detect
significant and biologically relevant changes in muscle microRNA expression. Participants
with either pre-diabetes or diabetes were obese (BMI30kg.m-2), while healthy participants
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had a BMI within the normal range. We cannot definitely determine whether the effects on
skeletal muscle miR expression are driven by obesity or type 2 diabetes through cross-sectional
comparisons of clinical data. However, through inclusion of an in vivo animal model where
diabetes developed in the absence of obesity and also in vitro cell culture studies, we were able
to further elucidate the relationship between miR expression and glucose metabolism. Our
combined experimental and clinical approach allowed us to identify changes of miR-194
expression across multiple species and metabolic tissues (skeletal muscle, adipose tissue) at dif-
ferent stages of the disease progression suggesting that miR-194 may be involved in the initial
cellular responses to hyperglycemia and be part of the early cellular events related to the patho-
genesis of type 2 diabetes. Our functional experiments in vitro have provided strong evidence
of the effects of miR-194 down-regulation on glucose metabolism; additional studies examin-
ing the effects of miR-194 inhibition in vivo are now warranted to confirm our data.
Likewise, functional studies should be carried on other microRNAs that showed significant
changes in our human cohort or in our animal model. Evaluation of the roles of these miRNAs
would provide a better understanding of their relative contribution to the pathogenesis of insu-
lin resistance and diabetes.
Translational potential
Epigenetics, in particular miRNAs, are considered important regulators of gene expression
which can permanently alter phenotype. Though the understanding of the involvement of
miRNAs in diabetes is in its infancy, advances in investigating the role of miRNAs in diabetes
may potentially provide a powerful tool to predict, diagnose, treat, and prognose diabetes in
the future [46].
Although we have not examined the mechanism by which miR-194 is down-regulated in
skeletal muscle in the current study, it could involve selective packaging into exosomes. Mea-
suring circulating miR-194 in the blood at different stages of the disease progression could
inform on the potential of miR-194 as an early biomarker of diabetes, long before the onset of
the disease. Indeed studies have demonstrated that miRNAs may act as potential biomarkers
for diagnosis and prognosis of diabetes [47–51].
Changes in muscle metabolism associated with diabetes likely have multiple origins. While
the aim of the current study was to identify miRs regulating glucose metabolism early in the
history of metabolic disease, future studies which identify the complex interactions between
miR expression and glucolipotoxic conditions in the context of metabolic disease are war-
ranted. For instance, miR-194 expression was found increased in C2C12 cells treated with pal-
mitate, and restored with oleate [52].
Conclusions
In summary, our data indicate that miR-194 is down-regulated early in the development of
insulin resistance and that this regulation is maintained through the progression towards type
2 diabetes. Furthermore, in vitro experiments showed miR-194 is involved in glucose uptake,
glycolytic breakdown and its incorporation into glycogen, as well as mitochondrial oxidative
capacity through mechanisms involving modulation of AKT, GSK3 and oxidative phosphory-
lation complexes. Taken together, our data suggest that the decrease in miR-194 expression
observed in insulin resistant muscle is an adaptive response to facilitate tissue glucose uptake
and metabolism in the face of insulin resistance. This aligns with the description of stress-
responsive miRNAs that are regulated to maintain physiological processes [53, 54]. MiR-194
regulation thus appears to limit metabolic disturbances in vitro, yet its decrease in vivo is not
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sufficient to combat the progression to type 2 diabetes and the role of other key miRs warrants
further investigation.
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